Blood contact with biomaterials triggers activation of multiple reactive mechanisms that can
impair the performance of implantable medical devices and potentially cause serious …

For more than 10 years, dual antiplatelet therapy with aspirin and clopidogrel has remained
the cornerstone of treatment for patients with acute coronary syndrome (ACS). The novel …

Guidelines, Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dual antiplatelet therapy, Acute
coronary syndromes, Coronary artery bypass grafting, Coronary artery disease, Drug-eluting …

Background Appropriate antithrombotic regimens for patients with atrial fibrillation who have
an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) …

Context High platelet reactivity while receiving clopidogrel has been linked to cardiovascular
events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue …

Antithrombotic drugs, which include antiplatelet and anticoagulant therapies, prevent and
treat many cardiovascular disorders and, as such, are some of the most commonly …

ContextFollowing percutaneous coronary intervention (PCI), short-term clopidogrel therapy
in addition to aspirin leads to greater protection from thrombotic complications than aspirin …

Most patients with atrial fibrillation (AF) and risk factors for stroke require oral anticoagulation
(OAC) to decrease the risk of stroke or systemic embolism. This is now best achieved with …

Background Mechanical reperfusion with stenting for ST-elevation myocardial infarction
(STEMI) is supported by dual antiplatelet treatment with aspirin and clopidogrel. Prasugrel, a …

In patients with stable CAD, PCI can be considered a valuable initial mode of
revascularization in all patients with objective large ischaemia in the presence of almost …